Etaracizumab, formerly referred to as MEDI523 and later LM609, represents a promising approach in antibody-mediated therapy. This monoclonal antibody is intended to specifically neutralize the activity of C1q, a critical component of the pathway involved in immune response . Research have investigated its therapeutic application in several inflamm